Oncolytics Biotech Files Routine February 6-K
Ticker: ONCY · Form: 6-K · Filed: Feb 14, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Feb 14, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, compliance
TL;DR
**Oncolytics Biotech filed a routine 6-K, no new material info in this cover page.**
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on February 14, 2024, for the month of February, as a routine report of a foreign private issuer. This filing, with Commission File Number 001-38512, indicates the company's compliance with SEC reporting requirements but the provided text does not contain specific news or financial updates.
Why It Matters
This filing is a standard regulatory submission for foreign private issuers, ensuring transparency and compliance with U.S. securities laws, but the provided text does not disclose new material information.
Risk Assessment
Risk Level: low — The filing is a standard regulatory cover page and does not contain any specific operational or financial news that would introduce new risks.
Key Players & Entities
- Oncolytics Biotech Inc. (company) — registrant
- SEC (company) — regulatory body
FAQ
What type of filing is this document?
This document is a Form 6-K, which is a Report of Foreign Private Issuer.
Who is the registrant that filed this document?
The registrant that filed this document is Oncolytics Biotech Inc.
What is the filing date of this 6-K?
The filing date for this Form 6-K is February 14, 2024.
What is the purpose of a Form 6-K?
A Form 6-K is used by foreign private issuers to furnish information required by Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Does this specific 6-K contain new material information or financial updates?
Based on the provided text, this filing is a cover page and does not contain specific news or financial updates.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2024-02-14 08:30:16
Filing Documents
- form6kgobletc4expansion.htm (6-K) — 18KB
- oncygobletc4expansion.htm (EX-99.1) — 27KB
- 0001129928-24-000006.txt ( ) — 46KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date February 14, 2024 Kirk Look Chief Financial Officer